[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 14, 2005

The RADAR Project and the FDA

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;294(10):1206-1207. doi:10.1001/jama.294.10.1206-a

To the Editor: The Research on Adverse Drug Events and Reports (RADAR) project described in the Special Communication by Dr Bennett and colleagues1 shows how a focused research team can aid postmarketing surveillance by actively investigating potential adverse drug reactions (ADRs). Operating out of a National Cancer Institute–designated comprehensive cancer center, the RADAR project is well-configured to address cancer and hematopoietic-related ADRs, an important category of adverse events often associated with drug exposures. Other organ-based specialists, such as hepatologists involved with the Drug Induced Liver Injury Network,2 similarly offer insights into drug-related illnesses of patients in their care.

First Page Preview View Large
First page PDF preview
First page PDF preview